Optimal prostate-specific antigen screening interval for prostate cancer

Date of this Version


Document Type

Journal Article

Publication Details

Citation only

D. Kobayashi, D., Takahashi, O., Fukui,T., & Glasziou, P.P. (2012). Optimal prostate-specific antigen screening interval for prostate cancer. Annals of Oncology, 23(5), 1250-1253

Access the journal

2012 HERDC submission. FoR code: 111717; 110399

© The Author 2011




Background: To identify the optimal interval for repeat prostate-specific antigen (PSA) testing to screen for prostate cancer in healthy adults.

Patients and methods: A retrospective cohort study was conducted on 7332 healthy males without prostate cancer at baseline from 2005 to 2008. Participants underwent annual health checkups including PSA testing at the Center for Preventive Medicine in Japan. Participants with high PSA (≥4.0 ng/ml) underwent further examination for prostate

cancer. A subgroup analysis was conducted age group (<50 years, ≥50 years). Results: Mean age was 50 years. Mean PSA at baseline was 1.2 ng/ml. In over 50-year group, for those with initial PSA of <1.0, 1.0–1.9, 2.0–2.9, and 3.0–3.9 ng/ml at baseline, the 3-year cumulative incidence of prostate cancer was 0%, 0.1%, 0.3%, and 5.7%, respectively. No prostate cancer was identified in those <50 years, regardless of PSA level.

Conclusions: If PSA screening is recommended, males >50 years with PSA of 3.0–3.9 ng/ml at baseline should undergo rescreening at 2 years. For men with PSA <3.0 ng/ml, PSA rescreening at intervals of ≥3 years is appropriate. PSA screening may not be indicated in males of <50 years of age

This document is currently not available here.



This document has been peer reviewed.